by EHP Online
January 14, 2004
From the
beginning of organized crop production through present-day agriculture,
mycotoxins--toxic metabolites produced by fungi--have presented health
risks to both human and animal populations. Mycotoxins are secondary
metabolites produced by certain molds that infect food crops in the
field and during storage. Depending on the quantities produced and
consumed, mycotoxins can cause acute or chronic toxicity in the animals
and humans who eat contaminated crops or foods prepared from them.
Health effects of mycotoxins may include immunological effects,
organ-specific toxicity, cancer, and, in some cases, death. Agricultural
workers are also at risk for dermal and respiratory exposures during
crop harvest and storage.
Mycotoxin contamination is a worldwide problem affecting staple crops
such as corn (maize) and small grains (such as wheat), as well as tree
nuts, peanuts, sorghum, and many others. Many countries regulate the
maximum allowable concentrations of specific mycotoxins in food
commodities and animal feed. Until recently, dietary and occupational
exposures were the primary areas of concern, but with growing attention
being paid to the problems associated with indoor molds and respiratory
exposures, researchers are recognizing that the potential scope of
mycotoxin exposures is broader than originally suspected. This scope now
includes inner-city environments, with a special focus on older or
poorly maintained structures that are more susceptible to harboring
molds.
Researchers are also recognizing that specific groups within a
population may be more vulnerable to exposure than the population at
large. For example, in the United States, the Hispanic community
consumes a greater quantity of corn products compared to the general
population. Because corn is vulnerable to contamination by several
mycotoxins, it is possible that individuals within the Hispanic
community are exposed to higher dietary levels of mycotoxins than the
average American. This higher exposure could place them at a greater
risk of health problems.
The effects of mycotoxins have been recorded for millennia in sources as
diverse as 5,000-year-old Chinese texts, the Old Testament of the Bible,
and numerous scientific journals. As research into these compounds and
their effects has accumulated over the last several decades, mycotoxins
have been revealed to be an extremely diverse group of compounds.
During the Middles Ages, periodic epidemics of St. Anthony's fire, now
known as ergotism, afflicted countless individuals who had consumed
moldy rye. Gangrenous ergotism, the form that inspired the medieval
name, was accompanied by fiery pain, swelling, and gangrene in the
limbs. Convulsive ergotism, a second form of the toxicosis, was
accompanied by convulsions and hallucinations, among other symptoms.
Both forms could be fatal. Research in the 1940s identified ergot
alkaloids produced by Claviceps spp. as the mycotoxigenic source
of ergotism. Ergotism has occurred very rarely in recent decades; with
regard to agricultural crops, current research focuses on the toxigenic
and carcinogenic potentials associated with molds including species of
Aspergillus and Fusarium. With regard to indoor molds and
respiratory health issues, Stachybotrys chartarum (formerly S.
atra) contributes a challenging new facet to the field of
mycotoxicology.
A Centerpiece of Mycotoxin Research
"Monolithic" is how John D. Groopman, a professor of environmental
health sciences at the Johns Hopkins University School of Public Health
in Baltimore, Maryland, describes the literature on
aflatoxins--mycotoxins produced by Aspergillus spp. "As far as
the epidemiology in people goes, the overabundance of literature covers
aflatoxins," he says. "Aflatoxin levels are regulated not only by the
Food and Drug Administration [FDA] and the U.S. Department of
Agriculture [USDA] but also in world commerce. I don't believe that's
true for almost any of the other mycotoxins." This emphasis reflects the
central role of aflatoxins, especially aflatoxin B1 (AFB1),
in mycotoxicological research since the early 1960s. Primarily produced
by A. flavus and A. parasiticus, AFB1 causes
liver and kidney toxicity in several species and is most prominently
known as a potent liver carcinogen in humans and animals. Aspergillus
spp. exist worldwide and live off of a number of crops, although corn
and peanuts are the most commonly contaminated commodities. A. flavus
and A. parasiticus are the most common forms of Aspergillus
and are also capable of producing other forms of aflatoxin.
Frequently, there is contamination with multiple forms of aflatoxin.
However, regardless of which aflatoxins are produced, AFB1 is
always among them, and it is the most toxic.
AFB1 has been shown to be mutagenic in many in vitro
model systems and is a proven carcinogen in many animal species,
including rodents and nonhuman primates. The primary cancer site in
these studies has been the liver, but in some cases a link has been
demonstrated to lung, kidney, and colon tumors. In human epidemiological
studies, chronic dietary AFB1 exposures have been strongly
linked to increased incidence of liver cancer. On the basis of this
information, AFB1 is classified as a known human carcinogen
by the International Agency for Research on Cancer and the National
Toxicology Program.
The carcinogenic potency of AFB1 is not manifested until it
undergoes activation by the cytochrome P450 and other oxidative enzymes.
These enzymes transform the aflatoxin into several products, including
the genotoxic AFB1-exo-8,9-epoxide. This epoxide can
be shunted by glutathione S-transferase in the liver, but some
will intercalate, or wedge itself, between DNA base pairs. In this
position, the epoxide rapidly reacts with the DNA to produce an N7-guanyl
adduct. As demonstrated in several animal models, these adducts are
produced in the greatest amounts in the liver, although some are also
produced in the kidney or lung. Through DNA repair and chemical
stability mechanisms, AFB1-DNA adducts can be removed and
excreted, but some adducts prove resistant to repair, thereby setting
the stage for mutation events and carcinogenesis. The potential for AFB1-induced
liver cancer is enhanced in individuals who are also infected with the
hepatitis B virus, a recognized carcinogenic virus. In AFB1-exposed
populations, examination of liver tumors reveals a high incidence of a
specific p53 tumor suppressor gene mutation. In AFB1-exposed
individuals infected with the hepatitis B virus, this mutation is
associated with 50-60% of the tumors. By understanding the mechanism of
action of AFB1, we are identifying guideposts for developing
intervention strategies, says Groopman.
The Depth of the Field
Not all carcinogenic mycotoxins act through a genotoxic mechanism, and
the fumonisins provide a case in point. The fumonisins--B1, B2,
and B3--are produced by Fusarium spp. that grow on
corn, most importantly F. moniliforme. In horses, relatively low
exposures to fumonisins have been shown to cause equine
leukoencephalomalacia, a disorder characterized by brain hemorrhage and
necrosis, followed by death. Horses may also suffer liver damage and
possibly a degree of kidney damage following dietary exposure to
fumonisins. Liver and kidney effects are more pronounced in other
species such as rodents, sheep, and rabbits. In swine, high doses of
exposure to fumonisins seem to especially affect the lungs, leading to
porcine pulmonary edema, a fatal condition in which fluid collects in
the lungs. Low exposures result in reduced feed consumption. Early
research in animals showed that fumonisins are potent cancer promoters
and potentially weak initiators. The National Toxicology Program, along
with the FDA's National Center for Toxicological Research in Jefferson,
Arkansas, and Center for Food Safety and Applied Nutrition in
Washington, DC, released the results of a massive study of the toxicity
of fumonisin B1 in May 1999. Their data showed that
fumonisins are carcinogenic in rodents, although response differed by
species and sex: male rats fed fumonisin B1 developed liver
and kidney cancers, while female mice developed liver cancer.
With regard to human toxicity, epidemiological data from southern Africa
and China suggest a strong link between dietary fumonisin exposure and
esophageal cancer. Human epidemiological studies, however, are not
definitive, says Ken Voss, a research pharmacologist at the USDA
Toxicology and Mycotoxin Research Unit in Athens, Georgia. "There are
suggestive data that the fungus and the fumonisins are associated with
esophageal cancer," he says. "But there are enough confounding dietary
and environmental factors that the correlation, although tantalizing and
suggestive, is as yet far from being proven." According to Voss, it has
been shown that fumonisins have measurable and repeatable toxic effects
in animal models.
Fumonisin toxicity seems to be mediated through inhibition of ceramide
synthase, a key enzyme in the sphingolipid biosynthetic pathway. "To put
it in layman's terms," says Voss, "the entire metabolism of
sphingolipids in the cell is disrupted." The potential ramifications of
this disruption can be far-reaching, he says. Until 15-20 years ago,
sphingolipids were considered as having a purely structural role in
cells; however, sphingolipid molecules and their derivatives are now
recognized as very biologically active compounds. These compounds, says
Voss, either initiate or act as messengers for many life-or-death
decisions that the cell has to make. Such decisions include whether the
cell embarks on apoptosis (cell death) or enters the cell cycle and
replicates. From this point, he says, there are a host of potential
steps and intermediaries leading to toxigenic or carcinogenic events.
Fusarium and Its Mycotoxins
In addition to fumonisins, Fusarium spp. produce several other
mycotoxins. F. graminearum and F. culmorum, molds that
contaminate corn, barley, wheat, and other crops, are capable of
producing the toxins zearalenone and deoxynivalenol (also called
vomitoxin). Different toxigenic species of Fusarium grow under
different sets of climatic conditions. "The production of these
compounds depends on a number of different conditions," says Retha
Newbold, a supervisory research biologist at the NIEHS. "Just to have a
product that is contaminated with mold is not to assume that mycotoxin
is present. The mold may be there, but it may produce different levels
of mycotoxins, or even different mycotoxins, depending on . . .
different conditions."
Although zearalenone has low acute toxicity, it exhibits marked
estrogenic effects in some species. Zearalenone and its metabolites,
particularly
-zearalenol and ß-zearalenol, have been shown to
bind to estrogen receptors in experimental systems. Their estrogenic
potential seems to fall between that of the endocrine-disrupting
organochlorine pesticides and the more estrogenic compound
diethylstilbestrol. Newbold indicates that the estrogenicity of
zearalenone and its metabolites differs depending on the tissue and the
species. For example, swine are especially sensitive and experience
hyperestrogenism leading to reproductive problems and infertility
following dietary zearalenone exposures. Other species such as cattle
and sheep seem more resistant to zearalenone but may still experience
some incidence of infertility, decreased milk production, and
spontaneous abortion after ingesting high doses. Still other species,
particularly chickens, appear even less sensitive.
It has been demonstrated that zearalenone and its metabolites may cause
carcinogenesis or teratogenesis in some species, but further research is
needed. Further research is also needed with regard to human toxicity.
Currently, the International Agency for Research on Cancer classifies
zearalenone as a 2A carcinogen, the highest possible classification when
categorical human epidemiology is absent. Several countries have already
established maximum allowable concentrations of zearalenone in food
ranging from 0 to 1,000 micrograms per kilogram. Data on human toxicity
are strongest with regard to estrogenic effects. For example,
zearalenone was considered a possible etiological agent for precocious
pubertal changes that were observed among Puerto Rican children for
several years beginning in 1979. Thousands of children, some of whom
were shown to have zearalenone or its derivatives in their blood,
reportedly experienced symptoms. However, as other estrogens (phytoestrogens
or residues of animal growth promoters) were potentially present in the
children's diets, this outbreak might have stronger implications with
regard to zearalenone's contribution to the total environmental estrogen
burden. Recent investigations using in vitro systems bolster the
idea that zearalenone interacts with human estrogen receptors. For
example, Craig Dees, a scientist in the Health Sciences Research
Division of the Oak Ridge National Laboratory in Tennessee, and
colleagues reported that zearalenone stimulates estrogen-receptor human
breast cancer cells to enter the cell cycle in vitro [EHP
105(suppl 3):633-636 (1997)].
"For people who are studying endocrine disruptors and who are actually
looking for some of the potential health effects during development,
this [mycotoxin] is one of their concerns," says Newbold. "But I
certainly don't think it has received the attention for human health
that it should have in the United States."
With regard to research, zearalenone seems to be overshadowed by
deoxynivalenol, a more demonstrably toxic Fusarium metabolite.
This mycotoxin has been linked to large-scale poisonings, human disease,
and animal production problems throughout the world. Deoxynivalenol is
one of the most common mycotoxins contaminating grains. It belongs to a
class of compounds called trichothecenes, to which several other
mycotoxins belong. Although deoxynivalenol is the least toxic of the
trichothecenes, its toxicity is still substantial in both animals and
humans. In large enough acute doses, it causes nausea, vomiting, and
diarrhea and destroys blood cells. Animals, particularly pigs,
demonstrate feed refusal and weight loss at lower doses. Deoxynivalenol
has also been shown to have immunological effects in animal models. For
example, research reviewed by James J. Pestka, a professor of food
science and human nutrition at Michigan State University in East
Lansing, and colleagues in the May 1996 issue of the Journal of
Toxicology and Environmental Health demonstrates that deoxynivalenol
interferes with normal immune system functioning in mice. They concluded
that deoxynivalenol induces cytokines, immune system factors that help
direct an inflammatory response. In the model they reviewed, mice
exposed to deoxynivalenol developed symptoms similar to human IgA
nephropathy, a kidney disorder characterized by inflammation.
Expanding Frontiers in Mycotoxicology
Trichothecenes may also be at the root of an outbreak of idiopathic
pulmonary hemorrhage among infants in Cleveland, Ohio [EHP
107(suppl 3): 495-499 (1999)]. Among infants, pulmonary hemorrhage, or
episodes of bleeding in the lungs, can arise from several causes such as
injury or some forms of pneumonia. Unexplained, ongoing episodes of
bleeding, as seen with the infant patients in Cleveland, is much rarer.
Between 1993 and 1998, physicians at the Rainbow Babies & Children's
Hospital in Cleveland saw 37 cases of pulmonary hemorrhage among infant
patients; in the preceding 10 years, only three such cases had been
encountered. Nearly all of the 37 infants were brought to the hospital
because of breathing difficulties and required intensive care and
ventilator support. Pulmonary hemorrhage wasn't always apparent before
breathing difficulties surfaced but was detected once respiratory
support began. Researchers suspected that some element in the infants'
home environments was responsible for the symptoms because in several
cases symptoms recurred when an infant returned to his or her home.
In a case-control investigation begun in November 1994 by the Centers
for Disease Control and Prevention, researchers found evidence that the
geographically clustered infants' homes were contaminated with S.
chartarum, a mold not commonly found in home environments. S.
chartarum is known to produce several trichothecenes, specifically
satratoxins and roridin, as well as phenylspirodrimanes, cyclosporin,
and a newly discovered class of compounds, the stachybocins. Researchers
hypothesized that the mycotoxins, in combination with other stressors in
the infants' environments such as tobacco smoke, caused the respiratory
ailment that claimed the lives of 12 of the 37 infants. "The primary
problem with indoor molds is that the health hazard is predominantly
linked to people who are atopic--that is, they tend to be allergic,"
says Dorr Dearborn, an associate professor of pediatrics and
biochemistry at the Case Western Reserve University School of Medicine
in Cleveland and one of the researchers associated with the ongoing
S. chartarum investigation. Says Dearborn, "What we're beginning to
realize more recently, which is not really well known in the medical
field, is that there are [indoor] molds--not just Stachybotrys,
but probably a larger list of them--that produce mycotoxins that can
have direct effects on health. This is still an area of both
speculation/conjecture and some knowledge, but it's an area of active
concern and with some research at least starting to be generated."
The precise mechanisms of the Stachybotrys mycotoxins are
unknown, explains Dearborn. The trichothecenes may be able to trigger or
aggravate an allergy problem directly, he says, but not through a
traditional immunoglobulin E (IgE) pathway. Typically, an allergic
response involves production of antibodies constructed from IgE against
the allergen and some form of inflammation (such as asthma). Pestka's
work to elucidate how deoxynivalenol induces nephropathy has shown that,
at low levels, the trichothecene induces inflammatory mediators. This
suggests a mechanism by which mycotoxins, including those produced by
Stachybotrys, may produce airway disease or skin reactions without
going through the typical IgE mechanisms, says Dearborn.
Further information on Stachybotrys toxicity is gleaned from
older literature describing agricultural exposures to the mold in
Eastern Europe and northern Russia during the 1940s and 1950s. In this
literature, the effects include bleeding in the nose and throat
(although not the lungs), skin irritation, and altered white blood cell
counts. "The cellular mechanism of trichothecenes is well established:
they are potent protein synthesis inhibitors," says Dearborn. Inhibition
occurs via a single binding site on the ribosome, the cellular location
of protein construction. Depending on the specific trichothecene,
construction breaks down during its initiation, elongation, or
termination stages, he explains. However, he continues, the details
behind their effects on the immune system remain unknown.
Dearborn and his associates are currently in the early stages of a
five-year grant from the NIEHS to develop an infant model for S.
chartarum exposure as an outgrowth of their investigations into the
Cleveland outbreak of idiopathic pulmonary hemorrhage. "In the Cleveland
situation we're dealing with an epidemiological association--that is,
we've found [the mold] in the houses of the cases more than we found it
in the control houses. The link is not absolute at all; it's simply an
epidemiological link," says Dearborn. One of the scientists' immediate
challenges comes in the form of identifying a biomarker for exposure, a
difficult task given how rapidly the suspected toxins are metabolized.
Finding a biomarker is difficult because suspected Stachybotrys
toxins are rapidly metabolized and most people do not form antibodies in
response to the mold. The researchers' early experiments to duplicate
the disorder in infant animals have been promising. "What we have shown
is that if the spores of Stachybotrys are instilled in the
tracheas of young rat pups, they will develop pulmonary hemorrhage.
Initial results suggest that we are on the proper route to develop an
infant model for the disorder," says Dearborn.
Areas for Further Research
The diverse spectrum of mycotoxins produced by S. chartarum
illustrates one of the more vexing issues in mycotoxicology: mycotoxins
usually occur in mixtures. As a result, researchers recognize that
interactions are possible although they are difficult to characterize.
There is particular interest in exploring potential synergies, or
interactions in which exposure to more than one mycotoxin results in a
multiplication, rather than an addition, of risks. "The kinds of
experiments that are necessary to elucidate the nature of synergy are
complicated," says J. David Miller, a professor of chemistry at Carleton
University in Ottawa, Canada, who recognized early on that the toxins
produced by molds are typically mixtures of toxins. Such experiments
would require a lot of resources that currently are not available, so
investigating potential additive effects or synergy between
mycotoxins--or between mycotoxins and other environmental factors--is,
for the most part, not a major research focus. Nevertheless, researchers
have commented, for example, on the potential interaction between
fumonisins and aflatoxin. For now, says Miller, the most important
synergy that has been investigated with regard to mycotoxins is the one
that exists between aflatoxin and hepatitis B.
Another area of mycotoxin research that seems ripe for further
investigation concerns defining the subtler effects of individual
mycotoxins. In the area of veterinary toxicology, pinning down
information on such effects is an especially active area of interest,
according to George Rottinghaus, a chemist in the toxicology section of
the University of Missouri Veterinary Medical Diagnostic Laboratory in
Columbia. "Those are what I call the gray areas," he says. "Everybody's
done acute, subacute, and that type of work, but it takes a lot more
effort to get into these more subtle changes. [With] a lot of these
subtle things, you really wouldn't have symptoms. It would be more of a
performance- or immune-type response effect that most people wouldn't
see." He offers an example: "All of a sudden your animals might be
sicker than they normally are . . . or they [would be] off 5-10% in milk
production, or they don't gain [weight] quite the way they were supposed
to." Rottinghaus points out that these symptoms can be attached to many
other factors, but it's hard to pin them to either mycotoxins or
alternative explanations.
Controlling Exposures and Mitigating Effects
The best means of preventing the health effects of mycotoxins is to
prevent exposure--a task more easily noted than achieved. In the
agricultural arena, postharvest control of storage fungi is handled
through proper drying and storing of grains. These measures are
accomplished with varying degrees of adequacy depending on the available
equipment, storage facilities, and other variables. Success in
preventing field contamination can be even more variable owing to
factors such as insect infestation, drought, or weather events such as
hail storms. Once crops are damaged, an opening appears for fungal
contamination. Whether or not fungi will exploit that opening depends on
other factors, including the prevailing temperature, humidity, and water
content. In some fields, microclimates may exist so that one part of the
field can be heavily contaminated while neighboring sections are
completely untouched.
|
|
Although use of antifungal
agents and other chemicals is potentially effective, researchers are
investigating several strategies that don't rely on chemical
applications. "A number of the corn companies are trying to develop
hybrids that are resistant to the Fusarium infection," says
Rottinghaus. According to Voss, researchers at the USDA are exploring
another avenue in investigations centering on potential biological
controls of fungal growth and toxin production in corn plants. The idea
behind their strategy is to use nontoxigenic bacterial or fungal species
as bioexclusion agents that would outcompete fungi in the field and in
storage. This technique would only be used for corn destined for animal
feed, and Voss indicates that USDA researchers anticipate some
commercial applications of the technique within the next five years.
In some areas of the world, fungal control techniques are more urgently
needed. Miller points out that in North America the population
experiences a relatively low risk from mycotoxins owing to a diverse
diet and the range of zones in which crops are raised. "In North
America, we produce large amounts of a crop, and we only use a small
percentage of it for human food. If we have a bad year in Texas, it's
unlikely it's [also] a bad year in Iowa. We have the luxury, by and
large, to pick and choose in terms of excluding crops from our food
system if it's necessary," he explains. For example, in 1996 wheat grown
in Michigan, Maine, and Ontario couldn't be used because it was heavily
contaminated with vomitoxin. However, because the commodity is also
grown, albeit in lesser quantities, in Alberta and the U.S. Pacific
Northwest, buyers could find supplies elsewhere. "In developing
countries, that luxury is not there," Miller says.
In recognition of this fact, researchers are attempting to find other
means of protecting populations from the health effects associated with
mycotoxin exposure. Much effort has been devoted to applying such
measures in AFB1-exposed populations. One technique has been
to promote vaccinations for hepatitis B in areas with high AFB1
exposures. Another strategy explores the potential for altering the
metabolism of the toxic compounds. Recently, human trials were conducted
with oltipraz, a compound that interferes with the mechanism of action
of aflatoxin. The trials were published in the February 1999 issue of
the Journal of the National Cancer Institute. "We'd like to
believe from the data we have from the oltipraz clinical trial that
agents that can blunt the metabolism of aflatoxin are certainly going to
be important in terms of preventing aflatoxin-mediated DNA damage," says
Groopman, who collaborated with researchers in China on this study.
"With the oltipraz intervention, we found that we can modulate the
metabolism of aflatoxins in people and shunt the metabolism toward
non-DNA-damaging species. If that can be replicated by other dietary
agents, that is probably going to be a very important way of intervening
in large populations," he concludes.
Efforts to control exposure to mycotoxins are certainly better today
than in ancient times, but they still are not perfect. For example, the
testing for mycotoxins such as aflatoxin only involves grains that enter
interstate commerce and thus doesn't protect people who might consume
highly contaminated locally grown crops. Other populations may face
greater risk simply because they consume higher-than-average amounts of
certain commodities or because they live or work in poorly maintained
buildings. Finally, research has primarily emphasized dietary routes of
exposure. Knowledge about the long-term effects of other exposures is
lacking. "The toxins that enter the crops we use for food . . . [are]
sort of a by-product of chemical warfare that's going on at a
microbiological level," says Miller. There are lots of experiments to
do, he muses, and not a lot of resources to do them.
For more information, contact:
Alan L. Wozniak, CIAQP
(800) 422-7873 ext. 802